Drug intelligence / Profile preview

SHR-1020 + albumin-bound paclitaxel

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

SHR-1020 combined with albumin-bound paclitaxel is an investigational combination therapy being studied for the second-line treatment of advanced pancreatic cancer. This combination works through multiple mechanisms including blocking tumor mitosis, inhibiting tumor angiogenesis, and inhibiting interstitial fibrosis to achieve anti-tumor effects. Albumin-bound paclitaxel (also known as nab-paclitaxel) is a solvent-free formulation of paclitaxel that uses albumin nanoparticles to deliver the active ingredient more effectively to tumor cells.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on SHR-1020 + albumin-bound paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-1020 + albumin-bound paclitaxel.

Explore the full profile